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Objectives:We assessed our pacemaker strategy, use of antitachycardia therapies, generator longevity, and need
for programming changes in patients having Fontan conversion with arrhythmia surgery.
Methods: Between 1994 and 2008, of 121 consecutive patients having Fontan conversion and arrhythmia sur-
geries, 120 patients underwent pacemaker implantation at the time of Fontan conversion (mean age 22.9  8.1
years). Prior pacemakers were in place in 32/120 (26.7%) patients. Between 1994 and 1998, single-chamber atrial
antitachycardia pacemakers were implanted (n¼ 12); atrial rate-responsive pacemakers (n¼ 31) were implanted
between 1998 and 2002. Dual-chamber rate-responsive pacemakers (n¼ 16) were used between 2002 and 2003,
and subsequently dual-chamber antitachycardia pacemakers (n ¼ 61) have become the pacemaker of choice.
Leads have evolved from transatrial endocardial leads to epicardial unipolar and subsequently bipolar leads.
Results:Among 87 patients with adequate follow-up, all are currently atrially paced at a minimum lower rate70
beats per minute. Single-chamber atrial pacemakers were implanted in 43 (antitachycardia in 12), and dual-cham-
ber pacemakers in 77 (antitachycardia in 61); multisite ventricular leadswere placed in 7 patients. Far-field R-wave
sensing in 78.6% of unipolar atrial leads led to use of epicardial bipolar leads. Late atrioventricular block (24%)
led to routine implantation of dual-chamber pacemakers. Antitachycardia pacing was utilized in 7%. One patient
required acute lead revision and 4 required late upgrade to dual-chamber pacemakers. There was no pacemaker-
related infection. Twenty patients required generator change, and the mean device longevity was 7.53 years.
Conclusions: Customized pacemaker therapy can optimize management of patients following Fontan conver-
sion. Device longevity is excellent. Based on our experience with 120 Fontan conversions, we recommend place-
ment of a dual-chamber antitachycardia pacemaker with bipolar steroid-eluting epicardial leads in all patients at
the time of the conversion.C
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DThe development of chronotropic incompetence following
Fontan-type repairs has been shown to correlate with the de-
velopment of atrial tachycardia.1-3 Fontan conversion with
limited right atrial ablation has been shown to decrease the
incidence of tachycardia, but approximately 25% in an ini-
tial series experienced recurrent atrial tachycardia.4 The
more extensively modified right atrial maze significantly re-
duced the incidence of recurrent tachycardia.5,6 These strat-
egies incorporated antibradycardia pacing at physiologic
rates in an attempt to limit the occurrence of atrial ectopy
and subsequent degeneration into atrial tachycardia, and
a small percentage of patients used antitachycardia pacing
protocols to treat tachycardia recurrences. Epicardial pace-
maker implantation can be performed safely in patients hav-
ing Fontan repairs, but the technological challenges and
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gle ventricle physiology has not been previously reported.7
We reviewed the usage and longevity of pacing systems in
120 consecutive patients having Fontan conversion with ar-
rhythmia surgery, including changing device selection, the
development of atrioventricular (AV) block, and the utiliza-
tion and efficacy of antitachycardia modalities.
METHODS
This was a retrospective, single-center, uncontrolled study and was re-
viewed and approved by the Institutional Review Board at Children’s Me-
morial Hospital. The charts of 120 consecutive patients having Fontan
conversion with arrhythmia surgery and pacemaker implantation at Chil-
dren’s Memorial Hospital between December 1994 and April 2008 were re-
viewed; 1 additional patient during this time period did not have pacemaker
implantation. All patients had functionally single-ventricle physiology: 98
had a dominant left ventricle, 15 had a dominant right ventricle, and 7
had complex single-ventricle anatomy. The median age at the time of their
first Fontan operation was 5.8 years (range, 1.1–35 years), at the time of
Fontan conversion was 21.6 years (range, 2.6–47.3 years); the median post-
operative interval was 15.8 years after the first Fontan operation. Patients
had a mean of 1.5 and median of 1 prior midline sternotomies. Prior pacing
systems had been implanted in 32/120 (26.7%) patients, for indications of
sinus bradycardia and antiarrhythmic drug usage in 24, antitachycardia pac-
ing in 6, and AV block in 2 patients.
Lead Selection and Implantation Technique
The type of pacemaker lead that we used evolved over time as technolog-
ical advances provided new alternatives. Initially, bipolar endocardial leadsardiovascular Surgery c Volume 138, Number 4 937
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DAbbreviations and Acronyms
AAIR ¼ atrial rate-responsive pacemakers
AAIT ¼ atrial antitachycardia pacemakers
AV ¼ atrioventricular
DDDR ¼ dual-chamber rate-responsive
pacemakers
DDDRT ¼ dual-chamber anti-tachycardia
rate responsive pacemakers
were used as epicardial leads but had poor lead longevity. When epicardial
steroid-eluting leads were produced, the longevity of epicardial leads be-
came acceptable. Most recently, when bipolar epicardial leads were manu-
factured, with superior sensing and pacing capabilities, these became the
leads of choice. Between 1994 and 1998, atrial lead implantation was per-
formed using transatrially placed endocardial steroid-eluting bipolar tine or
screw-in leads (Medtronic 4524, 4024, and 4068; Minneapolis, Minn) in 15
patients.8 The transatrial endocardial screw-in lead was placed through
a purse-string suture through the atrial wall into either the right or left atrial
appendage. Between 1998 and 2003, atrial leads were implanted epicar-
dially using unipolar steroid-eluting leads (Medtronic 4965) in 21 patients;
after 2003, bipolar steroid-eluting leads were used (Medtronic 4968) in 84
patients. A total of 21 unipolar and 99 bipolar atrial leads were implanted.
With epicardial placement, the atrial lead was placed on the native right
atrium anterior to the atriotomy. The left atrial dome was used when atrial
thresholds less than 1.5 Vwere not obtainable on the right atrium. Epicardial
steroid-eluting bipolar ventricular leads were placed on the diaphragmatic
aspect of the single ventricle. With ventricular thresholds greater than 1.5
V, a ‘‘scored’’ technique was used: adipose tissue was dissected and re-
moved, allowing placement of the standard bipolar epicardial leads directly
on the myocardium. When the scored technique did not achieve thresholds
less than 1.5 V with the epicardial bipolar lead, 2 screw-in non-steroid-elut-
ing unipolar leads (Medtronic 5071) were implanted using a stab technique
into the myocardium. The 2 screw-in unipolar leads were then connected
with a Y-adapter for bipolar configuration. Whenever possible, multisite
ventricular pacing leads (bipolar steroid-eluting) were placed in patients
with either complete AV block or patients whose ventricular function was
significantly depressed preoperatively or during warming. The additional
ventricular lead for multisite pacing was placed on the anterior superior as-
pect of the single ventricle to allow maximal distance between the 2 ventric-
ular leads.
The pacing strategy included atrial pacing above the intrinsic junctional
rate, at 110 to 120 beats per minute, in the immediate postoperative period,
and this was incrementally decreased in the first few days following surgery.
Chronic pacing was routinely set at a minimum of 70 to 80 beats per minute.
Chronic anticoagulation with warfarin was used in all patients for at least
1 year postoperatively because of the newly placed polytetrafluoroethylene
tube graft (W.L. & Associates Inc, Flagstaff, Ariz) from the inferior vena
cava to the pulmonary artery for the extracardiac Fontan. Patients with trans-
atrial endocardial pacing leads remained anticoagulated indefinitely, main-
taining international normalized ratio between 2 and 2.5.
Pacemaker Selection
The type of pacemaker selected evolved over time, depending on pace-
maker availability and expected arrhythmia recurrence. Initially single-
chamber atrial antitachycardia pacemakers (AAIT; Intermedics Intertach;
Sulzer Intermedics, Winterthur, Switzerland) were used. This pacemaker
was not available after 1998, and atrial rate-responsive pacemakers
(AAIR) were implanted between 1998 and 2002 (Medtronic Thera and
Kappa models). Beginning in 2002, dual-chamber rate-responsive pace-
makers (DDDR) were implanted to minimize the impact of far-field R-938 The Journal of Thoracic and Cardiovascular Surwave sensing, and the potential for late AV node dysfunction. Since
2003, dual-chamber antitachycardia rate responsive pacemakers (DDDRT)
were implanted as these devices became available (Medtronic AT 500, En-
Rhythm). All dual-chamber pacemakers were programmed in atrial rate-re-
sponsive pacing mode, with the exception of patients with complete or
advanced AV block. An epicardial defibrillator (Medtronic Gem III AT)
was implanted using a medium epicardial defibrillator patch (Medtronic
6721) on the anterior ventricular surface in 1 patient for secondary preven-
tion following resuscitation from ventricular tachycardia.
Lead and Device Assessment
Lead characteristics were assessed at the time of implantation. Pacing
thresholds were tested at 0.5-millisecond pulse width and were assessed
as low (<1.5 V), medium (1.5–2.5 V), and high (>2.5 V). Far-field R-
wave sensing was defined as significant if the R wave detected by the atrial
lead was greater than 0.75 mV. Pacing complications were classified as lead
dislodgement or acute postoperative pacing thresholds greater than 3.5 V.
Follow-up data were assessed from patient records or through follow-up
letters from referring physicians. Lead characteristics during follow-up were
assessed using threshold testing and/or programmed parameters; program-
ming at<3.5 V at 0.4 milliseconds was considered as a low threshold. De-
vice longevity was assessed as the time to generator replacement. The need
for dual-chamber pacing and antitachycardia pacing utilization and efficacy
was recorded.
Statistical analysis was performed using Fischer exact test.
RESULTS
Acute implantation data were assessed in all 120 patients.
However, follow-up data were available in a total of 87 pa-
tients. Thirty-three patients are excluded from data analysis
(in 19 patients, follow-up pacing data were not available as
they were referred from overseas and other institutions; 6 pa-
tients had orthotopic heart transplantation, and 8 patients
died during follow-up). There was only 1 perioperative mor-
tality unrelated to pacing issues.
Thirty-two patients had prior implantation of pacing sys-
tems: transvenous atrial pacemaker in 9 (3 antitachycardia,
6 rate-responsive), and23patientswith epicardial pacemakers
(atrial in 4, ventricular in 5, and dual-chamber in 14 patients).
At the time of surgery, significant atrial thrombi were identi-
fied on 3/9 (33.3%) transvenous leads; 1 patient had a major
cerebrovascular accident with resultant hemiplegia.
Acute Lead Implantation Thresholds
Pacing thresholds for atrial leads were low in 98 (81.7%)
and medium in 22 (18.3%) patients. In dual-chamber de-
vices, ventricular thresholds were low in 42 (54.5%) and
medium in 35 (45.5%) patients. It is often very difficult to
obtain adequate thresholds in these patients with dense scar-
ring secondary to multiple prior procedures. Acute lead revi-
sion was performed in 1 patient (0.8%) with a transatrially
placed endocardial atrial lead on postoperative day 2 due
to intermittent atrial noncapture. There was no significant
difference in atrial pacing thresholds between transatrially
placed endocardial versus epicardial leads (P ¼ .07) or be-
tween unipolar versus bipolar leads (P ¼ .118; see Table
1). Transatrial endocardial leads trended to have lower butgery c October 2009
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Dnot statistically significant acute implantation thresholds
(see Table 3). For ventricular leads, there was no statistical
difference in pacing thresholds between screw-in non-ste-
roid-eluting unipolar versus epicardial steroid-eluting bipo-
lar leads (P ¼ .455; see Table 1).
Devices and Pacing Modes
Pacing modes are summarized in Table 2. Among the 77
patients with dual-chamber pacemakers (DDDR and
DDDRT), 19 (24.7%) patients utilized dual-chamber pacing
mode acutely postoperatively. One patient had preexisting
complete AV block, 9 had acquired complete AV block (3
transient), and 9 (7.5%) had marked AV node dysfunction
during amiodarone infusion.
Multisite Pacing
Multisite ventricular pacing leadswere placed in 7 patients,
with utilization of multisite pacing in 4 patients. One patient
had preexisting complete AV block, 2 had acquired complete
AV block, and 1 patient had significantly depressed ventric-
ular function preoperatively. Multisite pacing effectively
reduced QRS duration only in the 1 patient with reduced ven-
tricular function; ventricular function improved postopera-
tively, but the relationship to multisite pacing was not clear.
Follow-up
Adequate pacemaker data were available for 87 patients.
For patients with atrial pacing systems, the median follow-
up period was 83 months, and for patients with dual-cham-
ber pacemakers, the median follow-up was 32 months. Six
patients (7.5%) take chronic antiarrhythmic medications at
mean follow-up of 46.3 months.
Pacing Therapies
Atrial antitachycardia pacing was utilized effectively for
termination of recurrent atrial tachycardia in 5/73 (6.8%)
patients (3 with AAIT pacemakers and 2 with DDDRT
pacemakers). Rate-responsive pacing was utilized in all
patients with such devices; rarely, patients requested this
programming off due to the sensation of palpitations. All pa-
tients use atrial antibradycardia pacing to maintain atrial
TABLE 1. Lead implantation data
No. of
leads
Low
threshold
(<1.5 V)
Medium
threshold
(1.5-2.5 V)
High
threshold
(>2.5 V) P value
Atrium
Transatrial 15 15 (100%) 0 0
Epicardial 105 83 (79%) 17 (16.2%) 5 (4.8%) .07
Unipolar 21 20 (95.2%) 1 (4.8%) 0
Bipolar 99 78 (78.8%) 16 (16.2%) 5 (5.1%) .118
Ventricle
Unipolar 21 10 (47.6%) 7 (33.3%) 4 (19%)
Bipolar 56 32 (57.1%) 21 (37.5%) 3 (5.4%) .455The Journal of Thoracic and Crates greater than 70 beats per minute. Among 77 patients re-
ceiving dual-chamber pacemakers, 16/77 (20.8%) patients
required dual-chamber pacing during chronic follow-up
due to the development of advanced AV block. Among
the 43 patients with single-chamber pacemakers (AAIT
and AAIR), 4 (9.3%) patients required late upgrade to
DDD pacemaker: 2 patients developed late AV block and
2 patients to differentiate far-field R-wave sensing versus re-
current atrial tachycardia. Overall, dual-chamber pacing was
utilized in 20/84 (24%) patients with adequate follow-up
data.
Unipolar Versus Bipolar Atrial Leads
Far-field R-wave sensing was present in 11/14 (78.6%)
patients with unipolar atrial leads and 16/73 (21.9%)
patients with bipolar atrial leads (P< .0001) (Table 3).
Pacemaker Longevity
Pacemaker replacement has been performed in 20/87
(23%) patients. Among these patients, the mean generator
longevity was 7.53 years. No patient required late lead revi-
sion due to fracture. One patient with heterotaxy syndrome,
preoperative AV block, permanent atrial fibrillation, and ad-
vanced ascites required revision of the ventricular lead 10
months postoperatively due to high pacing thresholds.
DISCUSSION
Optimizing pacing strategies was a challenging but impor-
tant adjunctive therapy in this series of 120 patients having
Fontan conversionwith arrhythmia surgery.Despitemultiple
TABLE 2. Pacing mode at follow-up pacemaker interrogation
Pacing mode
Device n AAI DDD
Median
follow-up (mo)
Single-chamber
Atrial
antitachycardia
12 12 144
Atrial rate-
responsive
31 31 4 (later upgrade
to DDD)
93
Dual-chamber
Rate-responsive 16 13 3 72
Antitachycardia 61 49 13 25
Multisite
antitachycardia
7* 3 4* 39
Multisiteþdefibrillator 1 0 1 46 (exp)
AAI,Atrial sense/pace mode;DDD, dual-chamber sense/pace mode. *Included patient
with defibrillator.
TABLE 3. Follow-up FFR sensing in atrial leads
Atrial leads/
thresholds
Negligible FFR
(<0.75 mV)
Significant FFR
(>0.75 mV)
Unipolar 3 11
Bipolar 57* 16
FFR, Far-field R wave. *P< .0001.ardiovascular Surgery c Volume 138, Number 4 939
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Dprior surgeries, debilitating arrhythmias, and chronic antiar-
rhythmic therapy, epicardial leads were implanted with low
or medium threshold characteristics in all patients. Anti-
bradycardia atrial pacing optimizes cardiac output and, we
believe, minimizes the opportunities for atrial ectopy precip-
itating tachycardia.2 Significant atrial thrombi were present
on 3/9 previously placed transvenous leads. We initially
used transatrial placement of endocardial leads; the availabil-
ity of steroid-eluting leads combined with thrombus seen on
existing transvenous leads led to the abandonment of transat-
rial lead placement. Acute lead revision was necessary in
only 1 patient, and no patient required reoperation for lead
fractures. Lead placement at the time of surgery is challeng-
ing, but these results are encouraging. The changing patterns
of device availability, a small but present incidence of recur-
rent atrial tachycardia, and technical limitations based on
anatomy required an evolving approach to device selection.
The utilization of bipolar atrial leads significantly reduced
the incidence of far-field R-wave sensing and the resultant
problems in tachycardia recognition. Antitachycardia atrial
pacing therapies were utilized in 6.8% of patients, reflecting
a decrease in atrial tachycardia with changing arrhythmia
surgery, but underscoring the potential for late arrhythmia
occurrence. This may be low, but it is very important. The
cost of the dual-chamber antitachycardia pacemaker is less
than a standard dual-chamber pacemaker.
Based on the need for dual-chamber pacing in up to 21%
of patients during midterm follow-up and the need for a ster-
notomy or thoracotomy for new lead placement, it has be-
come our standard practice to place epicardial ventricular
leads on all patients.
Ventricular lead placement could be challenging, requir-
ing either a ‘‘scored’’ or ‘‘stab’’ technique to achieve ade-
quate pacing thresholds in a small number of patients.
This is due to the amount of epicardial adipose tissue present
and the scar tissue from prior procedures.
Patients who had limited modified right atrial maze sur-
gery in the beginning of the series had a higher incidence
of recurrent atrial tachycardia4 and have successfully used
atrial antitachycardia pacing to terminate tachycardias.
With increasing complexity of anatomy and arrhythmia sub-
sets, antitachycardia pacing may become a more important
part of chronic recurrent atrial arrhythmia management.9
Patients with preexisting complete heart block or patients
at risk of developing complete heart block (L-transposi-
tion-type anatomy) may benefit frommultisite pacing. There940 The Journal of Thoracic and Cardiovascular Suare a small number of patients who developed marked AV
block during the initial postoperative intravenous amiodar-
one infusion and required transient dual-chamber pacing.
In our series, the number of patients using multisite pacing
was too small and follow-up was too short to comment on
eventual ventricular function outcome. Achieving optimal
thresholds is important to avoid the risk of repeat sternoto-
mies. Customized pacemaker therapy can optimize manage-
ment of patients following Fontan conversion. Based on our
experience with 120 Fontan conversions, we recommend
placement of a dual-chamber antitachycardia pacemaker
with bipolar steroid-eluting epicardial leads in all patients
at the time of the conversion.
There are several limitations of our study. This was a sin-
gle-center, retrospective uncontrolled study. All the patients
were operated on by the same 2 surgeons. The main limita-
tion of our study is the limited availability of complete fol-
low-up pacemaker parameters and outcomes. Because
most patients are referred from out of region and frequently
transition from pediatric to adult cardiologists, follow-up
data frequently rely on communications from patients.
Resynchronization therapy for single-ventricle patients
needs to be assessed with multicenter studies due to the
small number of patients at each institution.
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